SynthesisAesthetic plastic surgery2026
Prophylactic Local Antibiotic Therapy in Tissue Expander-Based Breast Reconstruction: A Systematic Review and Meta-Analysis.
Synthesis in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTissue Expander-based Breast Reconstruction (TEBR) is a common and effective post-mastectomy procedure, but surgical site infections (SSIs) and reconstruction failure remain major complications. While prophylactic local antibiotic therapy for tissue expansion (PLATE) may reduce these complications, standardized guidelines are lacking, and evidence is limited.
methodsA systematic search of PubMed, Cochrane Library, Embase, and Scopus was conducted from inception to June 2025 for studies evaluating PLATE in TEBR. Eligible studies included randomized controlled trials and observational studies reporting surgical site infections and expander loss. Data extraction and risk of bias assessment were performed independently using Newcastle-Ottawa Scale and Cochrane Risk of Bias tool. Meta-analyses were performed using random-effects models, with heterogeneity assessed via I
resultsEleven studies comprising 2,570 participants were included. PLATE was associated with a lower risk of overall infections (RR: 0.54, 95% CI: 0.38-0.77; p = 0.0006, I
conclusionPLATE may be associated with reduced rates of SSIs and expander loss in TEBR and could serve as a potential adjunct to systemic antibiotics. However, given the predominance of retrospective studies and underlying clinical heterogeneity, these findings should be interpreted as hypothesis generating, rather than definitive evidence. Larger, prospective trials particularly among high-risk populations are needed to confirm long-term safety, cost-effectiveness, and optimal delivery methods. LEVEL OF EVIDENCE III: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
42414645What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.